FE203799
Small molecule
FE203799 is one of 19 small molecule programs targeting Short Bowel Syndrome. It is currently in development.
1
Indications
2
Total Trials
0
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
28 competitors in Short Bowel Syndrome
#DrugCompanyPhaseTrials
1Eliquis
Bristol-Myers SquibbApproved
Byetta
AstraZenecaApproved
Victoza
Novo NordiskApproved
Ursodeoxycholic Acid
Daewoong Pharmaceutical Co. LTD.Approved
Growth Hormone
PfizerApproved
Dipeptidyl Peptidase 4 Inhibitor
Boehringer IngelheimApproved
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Rhgh
XXiamen Amoytop Biotech Co., Ltd.
Phase 3
Teduglutide /kg
TakedaPhase 3
Apraglutide
VVectivBio AG
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FE203799. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- GGlyPharma Therapeutics